Smith & Nephew plc vs Atlassian Corporation PLC — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.31B), while Atlassian Corporation PLC trades at $202.73 (market cap $49.56B). The key difference: Atlassian Corporation PLC is far larger — about 4.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Atlassian Corporation PLC for 64 Days on average.
| SNN | TEAM | |
|---|---|---|
Market Cap | $11.31B | $49.56B |
Volume | 1,050,005 | 1,747,462 |
Sector | Health | Technology |
52-Week High | $37.17 | $203.57 |
52-Week Low | $26.42 | $57.15 |
Typical Hold Time | 120 Days | 64 Days |
Enterprise Value | $14.35B | $49.56B |
Dividend Yield | 2.95% | — |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Atlassian (TEAM) trades at $203.57, up 4.94% with strong technical momentum and bullish moving averages. The stock shows improving fundamentals with revenue growth from $5.22B in 2025 to projected $6.6B in 2026, though it remains unprofitable with a -0.82% net margin. Recent earnings beats and accelerating cloud/AI adoption drive positive sentiment, with analyst consensus strongly bullish at 70% buy ratings.
Outlook remains positive due to cloud migration progress and AI product adoption, but investors face valuation concerns with elevated P/S of 7.75 and EV/EBITDA of 233.57. Key risks include persistent profitability challenges and competitive pressures in enterprise software. Current price exceeds consensus target of $191.16, suggesting near-term consolidation potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →